Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company